Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10
Authors:
- 1 May 2013
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 304 (9) , G781-G792
Abstract
Alternatively activated macrophages (AAMs) (or M2a) can inhibit colitis but may also be associated with fibrosis. Thus, by using the dinitrobenzene sulfonic (DNBS) murine model of colitis, this study aimed to determine whether 1 ) bone marrow (BM)-derived AAMs could reduce colitis, 2 ) any anticolitic effect of BM-AAMs was IL-10 dependent, and 3 ) repeated AAM treatments remained effective and were associated with fibrosis in the gut or other tissues. Balb/c mice received AAMs (106 intraperitoneally) from wild-type (WT) or IL-10−/− mice 48 h prior to DNBS (3 mg intrarectally) with disease assessed 72 h later, or they received three doses of DNBS at 2-wk intervals ± AAMs 6 h post-DNBS to mimic a treatment regimen. DNBS-treated mice developed colitis; this was significantly less severe in mice receiving WT AAMs and less so in animals given IL-10−/− AAMs, indicating a role for IL-10 in the inhibition of DNBS-driven colitis. Similarly, after the third AAM treatment lesser colonic histopathology was observed compared with time-matched DNBS-only-treated animals, and notably there was no evidence of increased fibroses in the colon, terminal ileum, lung, or liver of AAM-treated mice as assessed by quantitative PCR for prolyl-4-hydrolase, α-smooth muscle actin, and collagen (type IIIα) and histochemical and biochemical assessment of collagen deposition. This study provides mechanistic insight to the anticolitic capacity of AAMs and indicates that repeated adoptive transfer of ex vivo programmed BM-AAMs is safe and efficacious in the treatment of DNBS-induced murine colitis, providing additional support for their consideration as an immunotherapy.Keywords
This publication has 46 references indexed in Scilit:
- Alternatively activated dendritic cells regulate CD4+T-cell polarization in vitro and in vivoProceedings of the National Academy of Sciences, 2012
- Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsisGut, 2012
- Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I studyGut, 2010
- Macrophage Activation: Classical Vs. Alternative2009
- A Transient Breach in the Epithelial Barrier Leads to Regulatory T-Cell Generation and Resistance to Experimental ColitisGastroenterology, 2008
- Memory TH2 cells induce alternatively activated macrophages to mediate protection against nematode parasitesNature Medicine, 2006
- Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibodyInflammatory Bowel Diseases, 2006
- Whipple Disease: Intestinal Infiltrating Cells Exhibit a Transcriptional Pattern of M2/Alternatively Activated MacrophagesThe Journal of Infectious Diseases, 2005
- Induction of arginase I and II in bleomycin-induced fibrosis of mouse lungAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- Arginase modulates nitric oxide production in activated macrophagesAmerican Journal of Physiology-Heart and Circulatory Physiology, 1998